Endocrine Abstracts

Aim: To evaluate the efficacy and safety for first patients treated in our clinic with liraglutide.

Methods: Retrospective study of patients who started treatment with liraglutide in the last year in our department. We collected data on age, years of evolution, chronic complications, previous treatment, physical examination, analytical parameters and side effects.

Results: Fifty-four patients. Follow-up: 4–12 months. Mean age: 53.8 (S.D. 11.9) years, 44.8% men. Pretreatment: 37% insulin and OADs, 48.1% only OADs and 14.8% without treatment. There were significant differences between initial and final weight 116.5 (S.D. 34.12) vs 110.94 (S.D. 27.9) kg (P 0.007), mean blood glucose 150.81 (S.D. 56.49) vs 117.0 (S.D. 49.02) mg/dl (P 0.006), HbA1c: 7.24 (S.D. 1.67) vs 6.35 (S.D. 1.22)% (P 0.00), uric acid 5.93 (S.D. 1.66) vs 5.24 (S.D. 1.44) mg/dl (P 0.04), C Peptide: 2.88 (S.D. 1.10) vs 5.52 (S.D. 3.69) (P 0.04) and waist circumference 131.57 (S.D. 30.44) vs 124.14 (S.D. 21.48) cm (P 0.05). There were no differences in systolic or diastolic BP, LDL-c, HDL-c, TG, TG/HDL-C, creatinine, microalbuminuria, liver enzymes, TSH or calcitonin. The average weight loss was 5.62 (S.D. 6.86) kg, significantly higher in men than in women (8.93±6.96 vs 0.65±2.27, P 0.007), and correlated negatively with age (0.05) and positively with weight at the beginning (0.00). The mean decrease in HbA1c was 0.88±0.77 and correlated positively with baseline HbA1c (0.001). There was no correlation between the decrease in HbA1c and weight loss (0.31). Side effects: 4 patients reported nausea or postprandial discomfort that in 1 case led to suspension. No hypoglycemia or other side effects occurred.

Conclusion: i) Liraglutide treatment in obese patients with T2DM achieve an effective reduction of weight, waist circumference and HbA1c, with scarce sides effects.

ii) Patients who might benefit more from this treatment would be men with higher HbA1c and weight.